Plain-English translation of NCT06593392 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to see if it can safely reduce severe itching in teenagers with kidney disease who are on dialysis. Itching is a common and frustrating side effect of kidney disease and dialysis treatment. Researchers want to learn whether this medication can help teenagers feel better and improve their quality of life.
Severe itching affects many people on dialysis and can really impact sleep, mood, and daily life. Currently, treatment options for dialysis-related itching are limited, so researchers are studying this medication to see if it could offer teenagers a new way to manage this uncomfortable symptom.
You likely qualify if…
You likely don't qualify if…
Over about 17–18 weeks total, you would receive the medication intravenously during your regular dialysis sessions, 3 times per week, for 12 weeks. You would visit the dialysis center as you normally do, but the study team would give you the medication and monitor how you're feeling and how your body responds. The research team will ask you about your itching and how you're doing overall, and they'll take blood samples at certain times to check that the medication is working safely.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China